Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
599 studies found for:    Open Studies | "Carcinoid Tumor"
Show Display Options
Rank Status Study
21 Recruiting Study of Recombinant Adenovirus AdVince in Patients With Neuroendocrine Tumors; Safety and Efficacy
Condition: Neuroendocrine Tumors
Intervention: Drug: AdVince
22 Recruiting Molecular Analysis in Tissue Samples From Patients With Advanced or Metastatic Neuroendocrine Tumors
Condition: Neuroendocrine Tumor
Intervention: Other: laboratory biomarker analysis
23 Recruiting Pharmaco-immunological Study of Interferon-alpha and Metronomic Cyclophosphamide Association in Neuroendocrine Tumors
Condition: Neuroendocrine Tumors
Interventions: Drug: Metronomic cyclophosphamide;   Drug: Interferon-alpha
24 Recruiting Phase III Study of Sulfatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors
Condition: Neuroendocrine Tumors
Interventions: Drug: Sulfatinib;   Other: Placebo
25 Recruiting A Retrospective Data Analysis of Therapy With PRRT Combined With Lanreotide Autogel® for Neuroendocrine Tumours
Condition: Neuroendocrine Tumours
Intervention:
26 Recruiting Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumors
Condition: Neuroendocrine Tumors
Interventions: Drug: Lanreotide (Autogel formulation);   Drug: Placebo
27 Recruiting Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery
Condition: Neuroendocrine Tumors
Interventions: Drug: Sunitinib;   Drug: Everolimus;   Procedure: Surgery
28 Recruiting Efficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neuroendocrine Tumors.
Condition: Neuroendocrine Tumours
Intervention: Drug: Lanreotide (Autogel formulation) and Temozolomide
29 Recruiting Quality-Of-Life QLQ-GINET21 Questionnaire In The Treatment Of Patients With Gastrointestinal Neuroendocrine Tumours
Condition: Gastrointestinal Neuroendocrine Tumours
Intervention:
30 Not yet recruiting SUV on 68Ga-DOTANOC PET/CT and Ki-67 Index in Neuro-Endocrine Tumors
Condition: Neuroendocrine Tumors
Intervention: Drug: 68Ga-DOTANOC PET/CT
31 Recruiting A Phase 1 Study of PV-10 Chemoablation of Neuroendocrine Tumours (NET) Metastatic to the Liver
Condition: Neuroendocrine Tumors Metastatic to the Liver
Intervention: Drug: Rose bengal disodium
32 Recruiting Phase III Study of Sulfatinib in Treating Advanced Pancreatic Neuroendocrine Tumors
Condition: Neuroendocrine Tumors
Interventions: Drug: Sulfatinib;   Other: Placebo
33 Recruiting Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-DOTATATE in Advanced Gastro-entero Pancreatic Neuroendocrine Tumors
Condition: Neuroendocrine Tumors
Interventions: Drug: 177Lu-DOTATATE 25.9 GBq activity;   Drug: 177Lu-DOTATATE 18.5 GBq activity
34 Not yet recruiting Pancreatic Neuroendocrine Tumor:Factor of Surgery Influencing Survival
Condition: Pancreatic Neuroendocrine Tumor
Intervention: Procedure: pancreatectomy
35 Not yet recruiting Evaluation of Radiological Response of Pancreatic Neuroendocrine Tumors: Comparison Between the Choi and the RECIST Criteria
Condition: Pancreatic Neuroendocrine Tumors
Intervention:
36 Recruiting Personalized PRRT of Neuroendocrine Tumors
Conditions: Neuroendocrine Tumors;   Carcinoid Tumor;   Carcinoma, Neuroendocrine
Intervention: Drug: 177Lu-Octreotate
37 Recruiting The Safety And Efficacy Of Sunitinib In Chinese Patients With Progressive Advanced Or Metastatic Well-Differentiated Unresectable Pancreatic Neuroendocrine Tumors
Condition: Pancreatic Neuroendocrine Tumors
Intervention: Drug: sunitinib
38 Recruiting A Study Evaluating Lanreotide as Maintenance Therapy in Patients With Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors (REMINET)
Condition: Metastatic/Locally Advanced, Non-resectable, Duodeno-pancreatic Neuroendocrine Tumours
Interventions: Drug: lanreotide;   Drug: Placebo
39 Recruiting Prospective Comprehensive Molecular Profiling In Neuroendocrine Tumors
Conditions: Neuroendocrine Tumors;   Pancreatic Neuroendocrine Tumors
Intervention:
40 Not yet recruiting Phase II Study to Evaluate Efficacy of Rechallenge With Sunitinib in Patients With Metastatic Pancreatic Neuroendocrine Tumor (pNETs) Who Previously Failed to Sunitinib
Condition: Pancreatic Neuroendocrine Tumour Metastatic
Intervention: Drug: Sunitinib

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.